Podcasts about Mobi

On the CBS News Weekend Roundup, CBS News correspondent Peter King has the latest on the ambush attacks on two West Virginia National Guard members near the White House. Dozens have been reported killed and many more unaccounted for in a Hong Kong apartment complex fire. On the Kaleidoscope, King has a look at Monday's observance of World AIDS Day with DaShawn Usher, founder and CEO of MOBI, Mobilizing Our Brothers Initiative, in New York. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Was Sie erwartet Warum sich Unternehmen mit Mobilitätsmanagement auseinandersetzen sollten.Woraus eine Car-Policy besteht und wer über eine verfügen sollte.Warum es jetzt an der Zeit ist, sie grundsätzlich zu überdenken und zur Mobility-Policy weiterzuentwickeln.Welche Chancen, aber auch Konflikte daraus in der Praxis entstehen.Was die wichtigsten Erfolgsfaktoren für den Wandel von der Car-Policy zur Mobility-Policy sind – und wo Unternehmen häufig scheitern.Interviewpartner: Marc-Oliver Prinzing, Vorstandsvorsitzender des Bundesverbandes Betriebliche Mobilität e. V., Mannheim.Weitere Informationen--> Mobilitätsverband--> Nationale Konferenz für betriebliche Mobilität--> Video-Podcast "Müller & Prinzing" mit vielen weiteren wichtigen Impulsen! Im Interview: Marc-Oliver Prinzing Das Thema Unternehmen stehen vor einem Mobilitätswandel – weg von von der reinen Fokussierung auf den klassischen Dienstwagen, hin zu einer umfassenden Mobility-Policy, die alle Verkehrsmittel und Mitarbeitergruppen einbezieht.Marc-Oliver Prinzing, Vorsitzender des Bundesverbandes Betriebliche Mobilität (BBM), erklärt im Gespräch, wie dieser Wandel gelingen kann, welche Stolpersteine es gibt und warum Mobilität immer stärker Teil der Unternehmenskultur wird.Ein Gespräch über Verantwortung, Chancen – und den Mut, Mobilität neu zu denken.VeranstaltungsempfehlungÜber gutes Mobilitätsmanagement und die #NaKoBeMo® haben wir bereits im letzten Jahr berichtet. Wer Marc-Oliver Prinzing Live zu dem Thema hören will, der kann das am 25. und 26. November bei der 4. Nationalen Konferenz für Betriebliche Mobilität in Heidelberg in die Tat umsetzen.Warum diese Themen jetzt wichtig sindDie NaKoBeMo® 2025 zeigt, wie Mobilitätspolitik, Technologie und Unternehmenskultur zusammenspielen müssen, damit Mobilitätskonzepte wirksam werden – ökonomisch, ökologisch und sozial. „Eine Mobility-Policy richtet beispielsweise Mobilität an den Bedürfnissen des Unternehmens und Interessen der Menschen im Unternehmen aus. Sie verbindet Wirtschaftlichkeit, Nachhaltigkeit und Fairness für alle Beteiligten“, sagt Prinzing.Der Mix aus steuerlichen Neuregelungen, Nachhaltigkeitszielen und wachsendem Kostendruck zwingt Unternehmen, Mobilität neu zu denken. Zu den Lösungen können auch Mobilitätsbudgets, intelligente Rahmenbedingungen, multimodale Angebote gehören. Datenbasierte Entscheidungen werden zu zentralen Werkzeugen eines modernen Mobi-litätsmanagements.Mitreden, mitnehmen, umsetzen. Die NaKoBeMo® ist die Leitveranstaltung für alle, die Mobilität im Unternehmen strategisch weiterentwickeln wollen. Von Best Practices bis zu neuesten Forschungserkenntnissen – in Heidelberg wird deutlich, wie nachhaltige und innovative Mobilität Realität wird und werden kann. Insbesondere Unternehmen, Kommunen und kommunale Betriebe, die die betriebliche Mobilität mit Blick auf die Zukunft verantwortungsvoll gestalten wollen, sollten die Konferenz nicht verpassen. Sie erhalten eine klare Orientierung zu Regulierung, Finanzierung und Technologiepfaden – von betrieblicher Mobilität bis zur Flotten- und Dienstreisepolitik.

Dave Thomas, author of The Pragmatic Programmer, The Manifesto for Agile Software Development, Programming Ruby, Agile Web Development with Rails, Programming Elixir, Simplicity, and co-founder of the Pragmatic Bookshelf, speaks with SE Radio host Gavin Henry about building infrastructure for eBooks. They discuss what an eBook is, the various formats, what infrastructure is needed to build them, how an author writes an book, the history of the Pragmatic Bookshelf, how they have evolved, how to handle links within eBooks, why humans are so important in the writing process, and why AI can help with your writing -- once you've written your content. Thomas discusses PDFs, eBooks, Mobi files, ePub files, CI/CD pipelines, WYSWYG, Markdown files, Pragmatic Markup Language, embedding code, AI agents, images, printing PDFs, JVMs, Java, jRuby, and how Markdown won the plain text writing format wars. Brought to you by IEEE Computer Society and IEEE Software magazine.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

Digitālo brokastu 10. gadadienas ziņu topam pievienojas oriģinālā sastāva balss Mārtiņš “Kozmens” Kozlovskis! Par ko spriežam? Plāno slēgt daļu E-mobi elektroauto uzlādes tīkla staciju. Videospēle GTA 6 atlikta uz 2026. gada novembri. Terminatora cienīgs humanoīda robots XPeng Iron. Pārcenots auduma maisiņš iPhone viedtālrunim. MI kantrī dziedātājs Breaking Rust sasniedz Billboard pirmo vietu.  

We've got an update from Tandem Diabetes. We're talking about Libre 3 plus integration, Lyumjev approval, Mobi tubeless, extended wear infusion sets and a lot more with VP of Product Management Marisa Fienup. She's also answering your questions about tubing, alerts, and shares what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Information on RocketAP and other closed loop research Tandem earnings call info here  Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Scott talks with Marley, mom to one-year-old Bane, diagnosed after DKA and a life flight. From ICU to CGM and Mobi, she shares hard-won reality, faith, and growing TikTok advocacy. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** twiist AID System Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Scott talks with Marley, mom to one-year-old Bane, diagnosed after DKA and a life flight. From ICU to CGM and Mobi, she shares hard-won reality, faith, and growing TikTok advocacy. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

O jornalista Luís Costa Branco apresenta o Mobi Boom, um podcast semanal dedicado à mobilidade, inovação e qualidade de vida nas cidades. Pai de dois filhos e ciclista urbano há vários anos, Costa Branco partilha a sua paixão por formas de deslocação mais sustentáveis e práticas. Numa série de episódios curtos, o podcast vai explorar temas como carros elétricos, trotinetas, bicicletas, transportes públicos, logística urbana, jardins e cidades inteligentes. Uma proposta de escuta para quem acredita em cidades mais verdes, humanas e eficientes. Oiça e subscreva o Mobi Boom no Expresso ou na sua plataforma preferida de podcasts. Novos episódios todos os domingos. O primeiro sai dia 12 de outubro.See omnystudio.com/listener for privacy information.

This is the eighth chapter “Calm And Insight” from the book: Buddhadhamma: The Laws Of Nature And Their Benefits To Life by Bhikkhu P. A. Payutto (Somdet Phra Buddhaghosacariya) Published by Buddhadhamma FoundationCopyright © Buddhadhamma Foundation 2021Translated by Robin Philip Moore Editor: Bhikkhu Kovilo, typesetting: Bhikkhu Gambhīro Download this e-book in PDF, EPUB and MOBI formats atContinue reading "“Calm And Insight” Chapter 8 From Buddhadhamma: The Laws Of Nature And Their Benefits To Life"

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Bryant Garvin, a 20-year veteran of the digital marketing world, announced his new position as Operator in Residence at Triple Whale. This role leverages Triple Whale's massive data set (35,000+ stores, $55B+ GMP annually) to build better products for marketers and e-commerce operators. Garvin discussed his evolved perspective on attribution, emphasizing Triple Whale's holistic approach using AI and data integration beyond simple dashboards. He highlighted the power of MOBI, Triple Whale's platform, in providing data-driven insights for strategic planning, such as Prime Day optimization. The conversation also touched upon the importance of humanizing data, considering the broader context of marketing beyond immediate clicks, and the crucial role of product quality in marketing success. Garvin shared successful marketing strategies from his past, including adding value instead of discounting and leveraging Kickstarter for product launches. He championed YouTube as an underutilized e-commerce channel and cautioned against relying solely on quick wins, advocating for long-term brand building. Finally, he emphasized the importance of authenticity and human connection in marketing, even in the age of AI, and shared a personal anecdote about his childhood dream of becoming a paleontologist.

The Boox Palma 2, a compact e-reader with a 6.13-inch ePaper display and Android 13, is available at a discounted price for Prime Day. The device features access to the Google Play Store, 128GB of storage, Bluetooth support, a fingerprint reader, and an eight-day battery life. It supports multiple file formats, including PDF, EPUB, MOBI, and DOC, and allows users to download productivity and reading apps. The Prime Day deal is available through Amazon and Boox for a limited time.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

What if planning your next adventure felt more like a conversation with a trusted friend than a checklist? In this episode of Speaking of Travel, I'm joined by Anna Jaffe and Harriet Brown of Mobi.AI, a powerful new platform reimagining travel planning through the lens of empathy, technology, and storytelling. This is more than a travel episode. It's a love letter to curiosity, to wandering with purpose, and to a future where your travel tools know you crave hidden bookstores just as much as beach sunsets. Together we explore how AI is helping travelers find what really speaks to them beyond the filters and search engines and how this deeply personal approach is changing the way we explore the world. Anna and Harriet share why travel planning is so complex and so human and how AI tools are learning what you love and helping you discover more of it. This is a conversation about possibility, connection, and the beautiful future of travel where technology listens, learns, and helps us find joy in the journey. So if you've ever dreamed of travel planning that actually gets you, tune in. You'll hear about the tech, the heart, and the hope behind a smarter way to see the world.

Dr hab. Magdalena Bainczyk rozmawia z prof. Mariuszem Załuckim, Sędzią Sądu Najwyższego, o instytucjonalnej sile niemieckiego sądownictwa i jego wpływie na rolę Niemiec w Unii Europejskiej.

Yo Aunteas welcome DaShawn Usher and explore the themes of advocacy, community representation, and the importance of self-care in activism. They discuss the significance of creating spaces for marginalized voices, the role of joy in resistance, and the upcoming MOBI Fest, which celebrates black queer culture. The conversation also touches on navigating identity and the complexities of activism, emphasizing the need for intentionality and community support. In this lively conversation, Yo Aunteas and guest DaShawn Usher discuss their experiences at concerts, preferences for cities like Atlanta and New York, and reminisce about their favorite songs and artists. They delve into the anticipation surrounding upcoming tours, particularly the Brandy and Monica The Boy is Mine Tour, and reflect on the impact of iconic artists like Kelly Rowland, Beyonce, and Janet Jackson. The discussion culminates in a ranking of Beyonce's albums and a celebration of the music that has shaped their lives.   So, Get Your Cups Ready For Minoritea Report!   Time Stamps   00:00 Intro 02:20 Introducing DeShawn Usher 36:00 MOBI Fest: Celebrating Black Queer Culture 40:20 Curiositea   Follow Us-   Send Your Ask Yo Aunteas Questions To: TEA LINE  844-832-5463 Aya@minoriteareport.com or DM us on Social Media   MERCH: MinoriteaReport.com   Youtube: https://www.youtube.com/channel/UCo_xKK1VRhPrVMQxm1SzTCg   Instagram: https://www.instagram.com/minoriteareport/   Facebook: https://www.facebook.com/MinoriTeaReport/   Twitter: https://twitter.com/MTeaReport   Email Us- AYA@minoriTeaReport.com

Mobile attribution is getting better than ever before. And that's in spite of it becoming more and more complex.There's so many measurement methodologies. Advanced SAN. AEM. Advanced AEM. Unified Measurement. SKAN. AAK. Privacy Sandbox. GAID. IDFA. Probabilistic. Modeled.You name it, there's MORE of everything.But in spite of all that, mobile attribution is getting better. Way better. And maybe, it's actually BECAUSE of all that. And the great news: it's also getting EASIER.Makes sense? Insane?Impossible?Check out this convo in Growth Masterminds between John Koetsier and Singular CTO Eran Friedman

This is the seventh chapter “Supreme Peace: Nibbāna” from the book: Buddhadhamma: The Laws Of Nature And Their Benefits To Life by Bhikkhu P. A. Payutto (Somdet Phra Buddhaghosacariya) Published by Buddhadhamma FoundationCopyright © Buddhadhamma Foundation 2021Translated by Robin Philip Moore Editor: Bhikkhu Kovilo, typesetting: Bhikkhu Gambhīro Download this e-book in PDF, EPUB and MOBI formats atContinue reading "“Awakened Beings” Chapter 7 From Buddhadhamma: The Laws Of Nature And Their Benefits To Life"

“Ease of use is what drives adoption,” Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about what can fuel further insulin-pump penetration. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the AI-powered Control-IQ Plus algorithm, now approved for both type 1 and type 2 diabetes. The conversation also touches on the company’s international market strategy, value-based reimbursement and future product development, including the tubeless Sigi.See omnystudio.com/listener for privacy information.

Just Rambo this week. - New Song- Latest patch notes- Cloud vs Cam accounts- EE has an appstore advert being promoted by apple.- SHH loses Citadel in ER, SUS dropped on them.- PHPC joins SHH, - Kobra and SpacePope should be corpies- NE qq account has RMT sales - Mobi Mountain- Things I may have missed/comments

Émission du 21/03/2025 Représenter l'État ou être élue locale Troisième émission de cette série d'émissions « Explosons le plafond » mise en place avec Geoffrey, en service civique avec Mobiüs-Band, à l'occasion du mois des droits des femmes, à retrouver également sur le créneau de Sortez ! Problème de parité, difficulté d'accès aux postes à responsabilités, retour […] L'article La Méridienne x Möbius-Band : Explosons le plafond#3 est apparu en premier sur Radio Campus Tours - 99.5 FM.

Émission du 21/03/2025 Femmes à l’université et entreprenariat au féminin Quatrième et dernière émission de cette série d'émissions « Explosons le plafond » mise en place avec Geoffrey, en service civique avec Mobiüs-Band, à l'occasion du mois des droits des femmes, à retrouver également sur le créneau de La Méridienne ! Problème de parité, difficulté d'accès aux […] L'article Sortez ! x Mobiüs-Band : Explosons le plafond#4 est apparu en premier sur Radio Campus Tours - 99.5 FM.

Émission du 18/03/2025 Femmes dans les structures culturelles et d’innovation Première émission de cette série « Explosons le plafond » mise en place avec Geoffrey, en service civique avec Mobiüs-Band à l’occasion du mois des droits des femmes, à retrouver également sur le créneau de la Méridienne ! Et on commence fort avec Catherine Lenoble, directrice de […] L'article Sortez ! x Mobiüs-Band : Explosons le plafond#1 est apparu en premier sur Radio Campus Tours - 99.5 FM.

Émission du 20/03/2025 Femmes dirigeantes de structures culturelles Seconde émission de cette série d’émissions « Explosons le plafond » mise en place avec Geoffrey, en service civique avec Mobiüs-Band, à l'occasion du mois des droits des femmes, à retrouver également sur le créneau de Sortez ! Problème de parité, difficulté d'accès aux postes à responsabilités, retour sur […] L'article La Méridienne x Mobiüs-Band : Explosons le plafond#2 est apparu en premier sur Radio Campus Tours - 99.5 FM.

This is the sixth chapter “Supreme Peace: Nibbāna” from the book: Buddhadhamma: The Laws Of Nature And Their Benefits To Life by Bhikkhu P. A. Payutto (Somdet Phra Buddhaghosacariya) Published by Buddhadhamma FoundationCopyright © Buddhadhamma Foundation 2021Translated by Robin Philip Moore Editor: Bhikkhu Kovilo, typesetting: Bhikkhu Gambhīro Download this e-book in PDF, EPUB and MOBI formats atContinue reading "“Supreme Peace: Nibbāna” Chapter 6 From Buddhadhamma: The Laws Of Nature And Their Benefits To Life"

The Oregon Coast: 363 Miles of Possibilities and Experiences on The People's CoastIn this Outdoor Adventure Series podcast episode, we're thrilled to welcome Lynnee Jacks, the Industry Communications Coordinator for the Oregon Coast Visitors Association. Lynnee is passionate about sharing the natural beauty and diverse recreational opportunities found along the 363 miles of the Oregon coastline. Join us as we delve into the history, culture, and environmental stewardship that make the Oregon coast a cherished destination for visitors and locals alike and will inspire you to visit the People's Coast.DISCUSSION POINTSLynnee describes the Oregon Coast's diversity and beauty and her personal connection to the region.The ways has the Oregon Coast Visitors Association evolved over the years to address the changing needs and desires of tourists and locals.The "traditional" versus "non-traditional" adventures available on the Oregon Coast and how the region is diversifying its recreational opportunitiesThe key strategies the Oregon Coast Visitors Association uses to manage tourism impacts and ensure sustainable visitation.The ways the Oregon Coast region is working to make its beaches and trails more accessible to people with disabilities, as mentioned in the conversation.The ways Oregon Coast Visitors Association incorporate relaxation and wellness into their tourism offerings, and why is this important.The significance of the Oregon Coast's fishing industry and how the association aims to keep more local seafood in the region.The ways the Oregon Coast Visitors Association engages visitors in conservation and stewardship activities and the impact it has on local communities and ecosystems.Lynnee's "Aha Moment" related to the introduction of Moby Mats and why initiatives like this are important for locals and tourists on the coast.CONNECT WITH THE OREGON COASTTo see everything the Peoples Coast has to offer, visit the Oregon Coast website at https://visittheoregoncoast.com/ and follow their social media channels for the latest updates and travel inspiration:Facebook: https://www.facebook.com/ThePeoplesCoastInstagram: https://instagram.com/thepeoplescoastYouTube: https://www.youtube.com/channel/UCpqhcUNwZ9aBH-g6BcGLYOgNEXT STEPSVisit us at https://outdooradventureseries.com. We welcome likes, comments, and shares.KEYWORDSLynnee Jacks, The Peoples Coast, The Oregon Coast, Pacific Northwest Sustainability, Accessibility, Mobi-mat, Mental Health, Outdoor Adventure Series, Podcast#ThePeoplesCoast #TheOregonCoast #PNW #Tourism #Sustainability #Accessibility #MobiMat #MentalHealth #OutdoorAdventures #Podcast My Favorite Podcast Tools: Production by Descript Hosting Buzzsprout Show Notes by Castmagic Website powered by Podpage Be a Podcast Guest by PodMatch

Rambo, Jubi, and OC cant stop have a pre super bowl podcast where they talk about the game update, what it broke, all the rorq losses that happened, as well as some other things. Mobi mountain segment had some additional slides, and they give away a duo omega for the pvp ship winner of the week. 

Did you know how artificial intelligence is shaping the future of the hospitality industry?  In this episode of The Modern Hotelier, we sit down with Harriet Brown, VP of Product at Mobi.AI, to explore how artificial intelligence is revolutionizing the hospitality industry. Harriet shares insights from her impressive career, spanning AI, machine learning, and travel technology, including her time at Google and ITA Software.From personalization challenges to the future of AI in hospitality, Harriet offers a thought-provoking perspective on what's next for the industry. Plus, hear her advice for businesses hesitant to adopt AI and her favourite "aha" moments while building at Mobi. AI.Key Topics: How Mobi AI enhances decision-making and productivity for travelers and travel agents The importance of emotional loyalty in travel, alongside transactional loyalty What are Harriet's insights on adapting AI tools effectively and avoiding analysis paralysis Tips for creating loyalty through technology-enhanced experiences.If you're passionate about hospitality, tech innovation, or travel, this is an episode you don't want to miss!

No youtube stream on this episode.- Game News- Space Pope interaction- EE Spelling Bee, Asheeved vs Jubi- Mobi mountain week 4

00:00:00 - Intro 00:10:00 - patch notes 00:49:00 - AOS SoV Bill 00:54:00 - DDR Interview 01:20:00 - Weekend Update 01:28:00 - Community News 01:38:00 - AMA 02:02:00 - mobi mountain

Artificial Intelligence expert and founder of Bastyon, Daniel Satchkov, rejoins the program to discuss what AI is and what it is not. How they are likely propagandizing the public to believe AI is more than it it. We also discuss how those jobs that are akin to being part of an algorithm can be automated. This means most elite jobs such as MDs, marketing, and finance can be automated while the trades, nurses and other jobs are much harder to automate.You can learn more about Daniel Satchkov at https://bastyon.com/Daniel_Satchkov.Buy or learn more about the MOBI phone at https://bastyon.mobi/en/sarahwestall/

S6:E2 00:00:00 Intros (ad lib per hosts) 00:06:00 Game News (Official game announcements off Discord, Patch notes, leaked content) Leaked event stuff 00:33:00 Community News, Jubi joins another corp, Corp Tech stuff 00:37:40 Dark Aurora situation 01:10:00 Joda/Pand drama 01:17:00 Corp Tech 01:20:00 First Fortizar KM 01:24:00 New Kraken exec, SmoothMinimal, along with Sarp. 01:28:00 MOBI Mountain - Weekly PVP ranking

Stephanie uses a Mobi pump and has had type 1 for 26 years. Get Gvoke HypoPen CONTOUR NextGen smart meter and CONTOUR DIABETES app Learn about the Dexcom G6 and G7 CGM Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 JUICE CRUISE 2025 Screen It Like You Mean It Eversense CGM Learn about the Medtronic Champions This BetterHelp link saves 10% on your first month of therapy Try delicious AG1 - Drink AG1.com/Juicebox I Have Vision Use code JUICEBOX to save 40% at Cozy Earth  Learn about Touched By Type 1 Take the T1DExchange survey *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on Apple Podcasts. Thank you! The Juicebox Podcast is not a charitable organization.  

An airhacks.fm conversation with Phillip Krueger (@phillipkruger) about: early programming experiences with Visual Basic and Java, transition from actuarial science to computer science, first job at a bank working with Java Swing and RMI over CORBA, experience with J2EE and XML technologies, working with XML and XSLT, development of open-source Swing components, work on dotMobi sites for mobile phones in Africa, creation of API extensions for Java EE and MicroProfile, involvement in the MicroProfile GraphQL specification, joining Red Hat and working on quarkus, development of SmallRye GraphQL, improvements to OpenAPI support in Quarkus, work on Quarkus Dev UI, discussion about the evolution of Java application servers and frameworks, comparison of REST and GraphQL, thoughts on Java development culture in South Africa Phillip Krueger on twitter: @phillipkruger

Join me as I chat with Dr. Laurel Messer, Tandem's Senior Director of Medical Affairs, who brings 20+ years of experience in diabetes care, education, and research. 75% of clients coming to Risely are already using automated insulin delivery systems, which shows us that technology doesn't necessarily solve all of our problems living with T1D, right? Today's conversation with Dr. Messer offers insights on why users love Mobi, how to overcome barriers of use to Control IQ technology, what critical mindset shift is needed with automated insulin delivery, plus how to optimize technology and break old, unhelpful habits. With a deep understanding of patient care and technology, Dr. Messer offers a glimpse into the future of diabetes innovation that you can start being a part of now!Time Stamps:  (03:58) “I was a nurse first - nurses bear witness to the human experience”(06:25) What Surprised Her the Most About People Living with Diabetes (08:26) Her Role at Tandem (09:47) Control IQ Technology (11:20) User Feedback on Mobi Wearability, Ease of Use, and Control IQ(15:54) Tandem's Development of Mobi and Overcoming Barriers to Using Tech(17:51) Shifting Mindsets on Automated Insulin Delivery(21:50) Optimizing the Technology and Knowing Your Body's Patterns(26:08) How Old Habits Block Tech Optimization(31:09) Who is a Good Candidate for Automated Insulin Delivery Systems?(35:05) Where is Tandem and Technology Going?What to do now:Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop when new episodes drop.Doors are open for the January 2025 round of our signature group coaching program. Apply for coaching and talk to our team so you can reclaim the life you deserve. Check out the world's smallest, durable automated insulin delivery system, the Tandem Mobi HERE.Disclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan. 

Send us a textDiscover how Maxx turned setbacks into stepping stones, overcoming supply chain woes and financial turmoil, only to emerge with Madison Braids—a brand that skyrocketed to a $3 million triumph. Imagine having the insights to double, even triple your ROI with laser-focused strategies; this episode holds the keys to that paradigm shift.In this episode, Jordan West with Maxx Blank, a cofounder of Triple Whale, as he shares the incredible evolution of his ecommerce ventures. Our conversation navigates through Maxx's early days launching boutique operations like Ivy and Fig, to his current success with Triple Whale, a game-changing analytics platform for Shopify merchants. Join us as we explore Maxx's lessons learned from navigating supply chain challenges, leveraging Facebook ads, and developing cutting-edge solutions for the future of social commerce.Listen and learn in this episode!Key takeaways from this episode:Ecommerce Opportunities and Challenges: The initial phase (2015-2016) offered great opportunities in ecommerce via platforms like Facebook, but also brought challenges with supply chain and marketing.Targeting Niche Markets: Madison Braids' success shows the value of focusing on niche markets and how expanding to broader audiences can drive scalability.Robust Data Platforms: Triple Whale's evolution from a dashboard to a comprehensive data platform highlights the importance of meeting real business needs, especially in ad attribution and real-time analytics.Leveraging AI for Insights: The development of "Mobi" showcases the benefits of using AI tools to generate data insights and automate workflows, aiding effective business decisions.Adaptability: Maxx emphasizes staying flexible and skeptical of absolute predictions, which is crucial for navigating business changes and consumer shifts.Community Engagement: Events like the Whalies play a key role in building brand loyalty and recognition within the industry through community engagement.Pandemic-Induced Shifts: The ecommerce boom during COVID spotlighted the necessity for businesses to adapt strategies in response to external shifts.User-Driven Growth: Triple Whale's growth illustrates the power of user engagement in product development, leading to organic expansion.Today's Guest: Maxx Blank, cofounder of Triple Whale. Maxx is highly connected to the ecommerce industry, particularly in data analytics and marketing strategy. He is an expert in developing platforms that provide comprehensive analytics solutions for ecommerce businesses, addressing challenges like ad attribution, and evolving products to support multi-touch attribution and real-time data visualizations.Growth Plan: www.upgrowthcommerce.com/growMillion Dollar Offers: www.upgrowthcommerce.com/growIn this episode's sponsor is Revenued - is a financial technology company that provides businesses with revenue-based financing solutions. Instead of relying on credit scores or collateral, Revenued offers funding based on a company's revenue. This allows businesses to access capital quickly and repay it as they generate income. Learn more here: Revenued

This is the fourth chapter “Dependent Origination” in/from the book: Buddhadhamma: The Laws of Nature and Their Benefits to Lifeby Bhikkhu P. A. Payutto (Somdet Phra Buddhaghosacariya) Published by Buddhadhamma FoundationCopyright © Buddhadhamma Foundation 2021Translated by Robin Philip Moore Editor: Bhikkhu Kovilo, typesetting: Bhikkhu Gambhīro Download this e-book in PDF, EPUB and MOBI formats at the followingContinue reading "“Dependent Origination” Chapter 4 From Buddhadhamma: The Laws Of Nature And Their Benefits To Life"

White hat researchers managed to take over WHOIS for the .mobi TLD. Among other things, this discovery foretells the death of WHOIS as a valid email source for Domain Control Validation (DCV).

This week, we discuss IBM acquiring Kubecost, AWS moving OpenSearch to the Linux Foundation, and Amazon employees heading back to the office. Plus, some thoughts on what it means to be in "employee mode." Watch the YouTube Live Recording of Episode (https://www.youtube.com/watch?v=aWj5n7LWCdk) 485 (https://www.youtube.com/watch?v=aWj5n7LWCdk) Runner-up Titles That's a good looking setup there Feels like sweatpants London's busy, Amsterdam's laid back AIFinOps Mission Bankruptcy The settings page is more than 1 page Don't get turned into hamburger, that's the goal Feature checkbox acquisition. Employee Mode Using people as a whiteboard. Work on smarter things, not dumber things. Rundown Announcing Kubecost's Acquisition by IBM! (https://blog.kubecost.com/blog/ibm-acquisition-announcement/) AWS hands OpenSearch to the Linux Foundation (https://www.infoworld.com/article/3520875/aws-hands-opensearch-to-the-linux-foundation.html?utm_medium=social&utm_content=content&utm_campaign=organic&utm_source=twitter) Update from Amazon CEO Andy Jassy on return-to-office plans and manager team ratio (https://www.aboutamazon.com/news/company-news/ceo-andy-jassy-latest-update-on-amazon-return-to-office-manager-team-ratio) JPMorgan creates new role overseeing junior bankers as Wall Street wrestles with workload concerns (https://www.cnbc.com/2024/09/18/jpmorgan-investment-bank-creates-new-role-overseeing-junior-bankers.html) Relevant to your Interests OpenAI Fundraising Set to Vault Startup's Value to $150 Billion (https://www.bloomberg.com/news/articles/2024-09-11/openai-fundraising-set-to-vault-startup-s-value-to-150-billion) Lyft CEO keeps it real on his stock price compared to Uber (https://finance.yahoo.com/news/lyft-ceo-keeps-it-real-on-his-stock-price-compared-to-uber-230146967.html) We Spent $20 To Achieve RCE And Accidentally Became The Admins Of .MOBI (https://labs.watchtowr.com/we-spent-20-to-achieve-rce-and-accidentally-became-the-admins-of-mobi/) How China has ‘throttled' its private sector (https://www.ft.com/content/1e9e7544-974c-4662-a901-d30c4ab56eb7) Wall Street Curbs Young Bankers' Hours After Overwork Outcry (https://www.wsj.com/finance/banking/bank-america-jpmorgan-overtime-work-hours-f9f204a7) Unity is Canceling the Runtime Fee (https://unity.com/blog/unity-is-canceling-the-runtime-fee) Intel Awarded up to $3B by the Biden-Harris Administration (https://www.intel.com/content/www/us/en/newsroom/news/2024-intel-news.html) Free 'JavaScript' from Legal Clutches of Oracle, Devs Petition (https://thenewstack.io/free-javascript-from-legal-clutches-of-oracle-devs-petition/) Instagram makes teen accounts private by default (https://www.platformer.news/instagram-teen-accounts-private-default-daily-limit/?ref=platformer-newsletter) Cisco's second layoff of 2024 affects thousands of employees (https://techcrunch.com/2024/09/17/ciscos-second-layoff-of-2024-affect-thousands-of-employees/) Call For Proposals (CFP) | LF Events (https://events.linuxfoundation.org/kubecon-cloudnativecon-europe/program/cfp/) Londoners will soon see drones ferrying blood between hospitals (https://techcrunch.com/2024/09/17/londoners-will-soon-see-drones-ferrying-blood-between-hospitals/) Nonsense Polishing Cloth (https://www.apple.com/shop/product/MW693AM/A/polishing-cloth) United Airlines is adding free Starlink Wi-Fi to all of its planes (https://www.theverge.com/2024/9/13/24243594/united-airlines-free-starlink-wi-fi-connectivity) Founder mode, baby #tech #founder #foundermode (https://www.tiktok.com/t/ZTFFRvSv1/) Chipotle's New Guac Robots Can Peel Your Avocados in 26 Seconds (https://www.bloomberg.com/news/articles/2024-09-16/chipotle-cmg-robots-for-guac-and-bowls-are-ready-for-brisket-season) LinkedIn Roaster - Brutal honesty for your profile (https://liroast.web.app/) SpaceX Starlink has 2,500 airplanes under contract after United megadeal, director says (https://www.cnbc.com/2024/09/17/spacexs-starlink-has-2500-aircraft-under-contract.html) Passport renewals go digital to ease wait times for American travelers (https://www.axios.com/2024/09/18/online-passport-renewal-us-travelers?utm_campaign=editorial&utm_medium=social&utm_source=twitter) Conferences Cloud Foundry Day EU (https://events.linuxfoundation.org/cloud-foundry-day-europe/), Karlsruhe, GER, Oct 9, 2024, 20% off with code CFEU24VMW. VMware Explore Barcelona (https://www.vmware.com/explore/eu), Nov 4-7, 2024. Coté speaking. SREday Amsterdam (https://sreday.com/2024-amsterdam/), Nov 21, 2024. Coté speaking (https://sreday.com/2024-amsterdam/Michael_Cote_VMwarePivotal_We_Fear_Change), 20% off with code SRE20DAY. DevOpsDayLA (https://www.socallinuxexpo.org/scale/22x/events/devopsday-la) at SCALE22x (https://www.socallinuxexpo.org/scale/22x), March 6-9, 2025, discount code DEVOP SDT News & Community Join our Slack community (https://softwaredefinedtalk.slack.com/join/shared_invite/zt-1hn55iv5d-UTfN7mVX1D9D5ExRt3ZJYQ#/shared-invite/email) Email the show: questions@softwaredefinedtalk.com (mailto:questions@softwaredefinedtalk.com) Free stickers: Email your address to stickers@softwaredefinedtalk.com (mailto:stickers@softwaredefinedtalk.com) Follow us on social media: Twitter (https://twitter.com/softwaredeftalk), Threads (https://www.threads.net/@softwaredefinedtalk), Mastodon (https://hachyderm.io/@softwaredefinedtalk), LinkedIn (https://www.linkedin.com/company/software-defined-talk/), BlueSky (https://bsky.app/profile/softwaredefinedtalk.com) Watch us on: Twitch (https://www.twitch.tv/sdtpodcast), YouTube (https://www.youtube.com/channel/UCi3OJPV6h9tp-hbsGBLGsDQ/featured), Instagram (https://www.instagram.com/softwaredefinedtalk/), TikTok (https://www.tiktok.com/@softwaredefinedtalk) Book offer: Use code SDT for $20 off "Digital WTF" by Coté (https://leanpub.com/digitalwtf/c/sdt) Sponsor the show (https://www.softwaredefinedtalk.com/ads): ads@softwaredefinedtalk.com (mailto:ads@softwaredefinedtalk.com) Recommendations Brandon: iPhone Mirroring: Use your iPhone from your Mac (https://support.apple.com/en-us/120421) Matt: NSW Electoral Commission (https://vtr.elections.nsw.gov.au/LG2401) Coté: Code to Production: From Cloud to DevOps to Platform Engineering, with Purnima Padmanabhan (https://www.tanzutalk.com/e/purnima-career/) Photo Credits Header (https://unsplash.com/photos/aerial-view-photography-of-the-city-Dymu1WiZVko) Artwork (https://unsplash.com/photos/end-sign-on-beige-sand-TgjSku4-g6Q)

Josh and Kurt talk about some security researchers sort of taking over the .MOBI whois server. The story is a bit sensational, but we ask if it really matters? There are a lot of interesting possible attacks, but turning something like this into a good attack is really hard, maybe impossible. The researchers presented the findings in a very reasonable way. Show Notes We Spent $20 To Achieve RCE And Accidentally Became The Admins Of .MOBI Heinz says sorry for ketchup QR code that links to porn site

This is the third chapter “Three Characteristics” in/from the book: Buddhadhamma: The Laws of Nature and Their Benefits to Lifeby Bhikkhu P. A. Payutto (Somdet Phra Buddhaghosacariya) Published by Buddhadhamma FoundationCopyright © Buddhadhamma Foundation 2021Translated by Robin Philip Moore Editor: Bhikkhu Kovilo, typesetting: Bhikkhu Gambhīro Download this e-book in PDF, EPUB and MOBI formats at the followingContinue reading "“Three Characteristics” Chapter 3 From Buddhadhamma: The Laws Of Nature And Their Benefits To Life"

In this episode of the Stock Day Media Podcast, host interviews Josh Sodiatis, CEO of Peer to Peer Network (Mobi Card). Josh announces two major updates: the company's approval for crowdfunding via a FINRA-registered intermediary, allowing unaccredited investors to invest as little as $250, and a legal opinion ruling Mobi Coin as a utility token. He explains how these updates could positively impact the company's stock and investment opportunities. Josh also elaborates on Mobi Coin's role as a digital business card and the marketing potential of crowdfunding, emphasizing its democratizing effect on investment.

What is the best insulin pump? Today's guest would be the one to know. Gary Scheiner, author of Think Like a Pancreas, has tried 32 different pumps in his 39 years living with type one. Gary and I chatted about the early days of AID systems, his favorite AID system, looping, and several different pumps, including iLet, Medtronic, Mobi, and Tandem. We also peek into what the future might hold for insulin pumps. This episode is a great resource to help you determine which technology will be the best for YOU. Time Stamps:  (02:28) Keeping Up with Technology Advances(04:18) Gary's 39 Years with Diabetes and 32 Different Pumps (06:27) “It's not the tool, it's the user.”(07:40) “Is there a best pump?” and finding the right one(11:00) The Early Days of AID Systems(13:39) His Favorite Aid System (16:05) Looping (18:44) The Gap Between Health Care & Tools Education(21:57) The iLet Pump(25:26) “I don't like people to start on a pump without learning self-management skills.”(27:45) Medtronic (29:08) Mobi (29:58) Tandem (31:33) The Future of Insulin Pumps(35:16) “What does reclaim your rise mean to you?”What to do now:Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop when new episodes drop.Learn more about our 1:1 coaching programs HERE.  Learn more about Temp Monitor HERE Buy Temp Monitor HEREFind Gary on Instagram and his book Think Like a Pancreas on Amazon.Disclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan. 

This is the second chapter “Six Sense Spheres” in/from the book: The Laws of Nature and Their Benefits to Lifeby Bhikkhu P. A. Payutto (Somdet Phra Buddhaghosacariya) Published by Buddhadhamma FoundationCopyright © Buddhadhamma Foundation 2021Translated by Robin Philip Moore Editor: Bhikkhu Kovilo, typesetting: Bhikkhu Gambhīro Download this e-book in PDF, EPUB and MOBI formats at the followingContinue reading "“Six Sense Spheres” Chapter 2 From Buddhadhamma: The Laws Of Nature And Their Benefits To Life"

In his best-selling book, Sapiens, Yuval Noah Harari describes the most important feature that separates human beings from all other species on the planet: Imagination. We have the ability to imagine something that does not (yet) exist, communicate the concept to others and persuade them to believe it. As a concrete example, he cites the limited liability company, an idea first hatched by the Dutch back in the 1600s. Today we are going to explore the imaginative idea of Web 3.0, an ambitious project to take usout of the quagmire that has become Web 2.0. The basic goal is to create a private internet that is much safer and more efficient than what we have today. Getting there will require imagination, education and a lot of believing. To get us on the path, we are very pleased to have as our guest Tram Vo, co-founder of MOBI, an organization that is building the infrastructure to make Web 3.0 possible. 

In this podcast episode, Andrew interviews Joshua Sodaitis, CEO of Peer to Peer Network, about their product, the Mobi Card. The Mobi Card is a digital business card platform that allows for easy sharing of multimedia content across social networks. Joshua highlights its growth, with an 832% user increase shortly after launch, and discusses future enhancements like enterprise signups. He outlines revenue strategies, including advertising and subscriptions, and teases the reintroduction of the Mobi Coin reward program. Listeners interested in the Mobi Card can find more information or download the app from the company's website or app stores.

Approved last year, Tandem's Mobi is now widely available. We're getting an update from Ben Mar, Director of Product Marketing, on the features of the Mobi that make this tiny pump different and we look ahead to what Tandem is working on next. Ben also answers your questions about everything from algorithm updates, international access, and much more This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Tandem announces it's taking orders and starting to ship the Mobi pump, Insulet gets European approval for the Abbott Libre integration with Omnipod 5, new study looks at type 2 remission and gastric bypass surgery, one type of medication seems to do a much better job preventing kidney stones in people with type 2, big new grant to look at exercise and type 1 and a look back at diabetes at the Super Bowl. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com